Cantor Fitzgerald initiated coverage of Phathom Pharmaceuticals (PHAT) with an Overweight rating and $23 price target The firm cited ...
In a report released today, Annabel Samimy from Stifel Nicolaus maintained a Buy rating on Phathom Pharmaceuticals (PHAT – Research Report), ...
Hosted on MSN29d
Phathom Pharmaceuticals COO Nabulsi sells $51,956 in stockPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a $484 million market cap biotech company, reported that its Chief Operating Officer, Azmi Nabulsi, sold shares of the company's common stock.
Phathom Pharmaceuticals (PHAT) stock rises as Cantor Fitzgerald issues an Overweight rating, rejecting its IP-rights related risk. Read more here.
Stifel analysts have maintained a Buy rating and a $28.00 price target for Phathom Pharmaceuticals (NASDAQ:PHAT), focusing on the company's recent developments. Currently trading at $5.59, ...
FLORHAM PARK, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for ...
Avi Kapoor "Top Pick for 2024": Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales ...
Phathom Pharmaceuticals FLORHAM PARK, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback